On October 7, 2020, GlycoMimetics, Inc. (the "Company") reported that it entered into a Sales Agreement (the "Agreement") with Cowen and Company, LLC ("Cowen") under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, par value $0.001 per share (the "Common Stock"), having an aggregate offering price of up to $100,000,000 after the date of the Agreement through Cowen as its sales agent (Filing, 8-K, GlycoMimetics, OCT 7, 2020, View Source [SID1234568188]). Also on October 7, 2020, the Company filed a prospectus supplement offering up to $100,000,000 of shares of its Common Stock in accordance with the Agreement, on the Company’s Registration Statement on Form S-3 (No. 333-231577). The Agreement replaces the prior Sales Agreement between the Company and Cowen, dated September 28, 2017 (the "Prior Agreement"). The Company sold an aggregate of $34.6 million in shares of Common Stock under the Prior Agreement. As a result of the expiration of the Company’s Registration Statement on Form S-3 (No. 333-220697), the parties have completed their obligations under the Prior Agreement.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Cowen may sell the Common Stock under the Agreement by any method permitted by law deemed to be an "at the market" offering as defined in Rule 415 of the Securities Act of 1933, as amended, including without limitation sales made by means of ordinary brokers’ transactions on The Nasdaq Global Market or otherwise at market prices prevailing at the time of sale, in block transactions, or as otherwise directed by the Company. Cowen will use commercially reasonable efforts to sell the Common Stock from time to time, based upon instructions from the Company (including any price, time or size limits or other customary parameters or conditions the Company may impose). The Company will pay Cowen a commission equal to three percent (3.0%) of the gross sales proceeds of any Common Stock sold through Cowen under the Agreement, and also has provided Cowen with customary indemnification rights. In addition, the Company has agreed to reimburse certain legal expenses and fees by Cowen in connection with the offering up to a maximum of $50,000.
The Company is not obligated to make any sales of Common Stock under the Agreement. The offering of shares of Common Stock pursuant to the Agreement will terminate upon the earlier of (i) the sale of all Common Stock subject to the Agreement or (ii) termination of the Agreement in accordance with its terms.
The foregoing description of the Agreement is not complete and is qualified in its entirety by reference to the full text of the Agreement, a copy of which is filed herewith as Exhibit 1.1 to this Current Report on Form 8-K and is incorporated herein by reference.
This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy the securities discussed herein, nor shall there be any offer, solicitation, or sale of the securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.